Ginkgo Bioworks (US:DNA) ZACKS·2025-10-28 23:16Core Viewpoint - Ginkgo Bioworks Holdings, Inc. is experiencing a decline in stock performance and is facing significant challenges in its upcoming financial results, with expectations of decreased earnings and revenue compared to the previous year [1][2][3]. Company Performance - The stock closed at $12.74, reflecting a -4.85% change from the previous day, underperforming against the S&P 500's gain of 0.23% [1]. - Over the past month, the stock has increased by 1.21%, which is lower than the Medical sector's gain of 5.57% and the S&P 500's gain of 3.57% [1]. Upcoming Financial Results - The projected EPS for the upcoming release is -$1.24, indicating a 14.81% decline compared to the same quarter last year [2]. - The consensus estimate for quarterly revenue is $39 million, down 56.2% from the year-ago period [2]. Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of -$5.27 per share and revenue of $181 million, representing year-over-year changes of +49.13% for earnings and -20.28% for revenue [3]. Analyst Estimates and Market Sentiment - Recent changes to analyst estimates reflect shifting business dynamics, with upward revisions indicating analysts' positive outlook on the company's operations [4]. - The Zacks Rank system, which assesses these estimate changes, currently ranks Ginkgo Bioworks Holdings, Inc. at 3 (Hold) [6]. Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 89, placing it in the top 37% of over 250 industries [7]. - Research indicates that higher-ranked industries tend to outperform lower-ranked ones by a factor of 2 to 1 [7].